Curi RMB Capital LLC Buys 13,126 Shares of Neogen Co. (NASDAQ:NEOG)

Curi RMB Capital LLC raised its position in shares of Neogen Co. (NASDAQ:NEOG) by 3.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 421,244 shares of the company’s stock after purchasing an additional 13,126 shares during the period. Curi RMB Capital LLC owned 0.19% of Neogen worth $7,081,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of NEOG. Vanguard Group Inc. grew its stake in shares of Neogen by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 19,715,974 shares of the company’s stock worth $311,118,000 after acquiring an additional 169,237 shares during the period. Select Equity Group L.P. boosted its position in Neogen by 23.1% during the second quarter. Select Equity Group L.P. now owns 15,530,439 shares of the company’s stock worth $242,741,000 after purchasing an additional 2,914,893 shares during the period. William Blair Investment Management LLC increased its stake in shares of Neogen by 64.7% in the second quarter. William Blair Investment Management LLC now owns 12,013,072 shares of the company’s stock worth $187,764,000 after purchasing an additional 4,717,696 shares in the last quarter. Conestoga Capital Advisors LLC raised its position in shares of Neogen by 24.5% in the third quarter. Conestoga Capital Advisors LLC now owns 8,706,224 shares of the company’s stock valued at $146,352,000 after purchasing an additional 1,711,238 shares during the period. Finally, Bamco Inc. NY lifted its stake in shares of Neogen by 10.3% during the 1st quarter. Bamco Inc. NY now owns 7,304,967 shares of the company’s stock valued at $115,272,000 after buying an additional 680,668 shares in the last quarter. 96.73% of the stock is owned by hedge funds and other institutional investors.

Neogen Stock Down 3.6 %

Shares of Neogen stock opened at $14.64 on Friday. The company’s 50-day moving average price is $15.31 and its 200-day moving average price is $15.41. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.41 and a quick ratio of 2.79. Neogen Co. has a 12-month low of $11.46 and a 12-month high of $20.89.

Neogen (NASDAQ:NEOG) last posted its earnings results on Thursday, October 10th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $217.00 million during the quarter, compared to analysts’ expectations of $215.05 million. Neogen had a positive return on equity of 2.80% and a negative net margin of 2.58%. The business’s revenue for the quarter was down 5.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.11 earnings per share. As a group, research analysts expect that Neogen Co. will post 0.5 earnings per share for the current year.

Insider Activity at Neogen

In related news, CEO John Edward Adent acquired 14,500 shares of the firm’s stock in a transaction that occurred on Friday, October 11th. The shares were bought at an average cost of $13.80 per share, for a total transaction of $200,100.00. Following the completion of the transaction, the chief executive officer now owns 216,477 shares in the company, valued at approximately $2,987,382.60. This trade represents a 7.18 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.13% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on NEOG. StockNews.com upgraded shares of Neogen to a “sell” rating in a research note on Monday, September 30th. Piper Sandler lifted their price target on Neogen from $17.00 to $17.50 and gave the company a “neutral” rating in a research report on Tuesday, August 6th.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.